Drug Profile
Reltecimod - Atox Bio
Alternative Names: AB-103; p 2 TALatest Information Update: 28 Dec 2022
Price :
$50
*
At a glance
- Originator Atox Bio
- Class Antibacterials; Peptides
- Mechanism of Action CD28 antigen modulators; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Skin and soft tissue infections
- Phase III Acute kidney injury; Peritonitis
- No development reported Sepsis
Most Recent Events
- 28 Dec 2022 No development reported - Phase-III for Acute kidney injury in Netherlands (IV)
- 28 Dec 2022 No development reported - Phase-III for Peritonitis in Netherlands (IV)
- 10 Dec 2020 Preregistration for Skin and soft tissue infections (In the elderly, In adults, In adolescents, In children) in USA (IV)